Gamabufotalin Suppresses Colorectal Cancer Growth via Oxidative Stress-Induced Apoptosis and DNA Synthesis Inhibition

Hui Nie1, Anfang Cui2, Zhicheng Sun3

  • 1School of Pharmacy, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, China.

Abstract

Insights

Gamabufotalin (GA) shows potent anti-colorectal cancer (CRC) activity by inducing cell death and halting proliferation. This compound effectively suppresses tumor growth in vivo with minimal toxicity, offering a promising new therapeutic avenue.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) remains a leading cause of cancer mortality globally.
  • There is a critical need for novel, effective, and less toxic therapeutic agents for CRC.
  • Gamabufotalin (GA), a bufadienolide, exhibits potential antitumor activity, but its mechanisms in CRC require elucidation.

Purpose of the Study:

  • To investigate the therapeutic efficacy of Gamabufotalin (GA) against colorectal cancer (CRC).
  • To explore the underlying molecular mechanisms of GA's action in CRC.

Main Methods:

  • Utilized in vitro assays (cell viability, colony formation, EdU, cell cycle, apoptosis, ROS, mitochondrial potential) and in vivo xenograft models.
  • Integrated transcriptomic and proteomic profiling to identify molecular targets.
  • Validated GA's efficacy and toxicity in a nude mouse model.

Main Results:

  • GA demonstrated potent, dose-dependent anti-CRC activity in vitro (IC50: 24-30 nM) with high selectivity.
  • GA induced mitochondrial apoptosis via reactive oxygen species (ROS) generation and cell cycle arrest, inhibiting DNA synthesis.
  • Omics analysis revealed TP53I3/PIG3 upregulation and RFC3/NUCKS1 downregulation as key mechanisms.
  • GA suppressed tumor growth in vivo without observable systemic toxicity.

Conclusions:

  • Gamabufotalin (GA) selectively and potently inhibits CRC via ROS-mediated apoptosis and proliferation suppression.
  • GA possesses a favorable therapeutic index and defined molecular targets.
  • GA presents a promising therapeutic candidate for colorectal cancer treatment.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...